ARM Technology Platform
We are leveraging our expertise in T cell biology and protein engineering to develop a novel class of Adaptive Immune Response Modulators (ARM) designed to address clinically validated drug targets. Our ARM product candidates have potential broad applicability across multiple disease areas, including autoimmune diseases.
While the traditional class of TCE therapeutics have displayed substantial activity, their use has presented limitations such as durability of response and overactivation of the immune system leading to cytokine release syndrome (CRS).
Janux evaluated numerous modifications of bispecific T-cell engagers to address key limitations of contemporary approaches, and ARM is the result.
